Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

Loxo data on the RET inhibitor LOXO-292 impressed at ASCO, so much so the company is looking to talk to regulators about the results after only a single-arm Phase I trial – but it's not a silver bullet as a tissue-agnostic treatment. Data on a separate target, PI3K, underwhelmed in breast cancer. Tissue of origin remains important, though the reasons why are not entirely understood. 

chess

Loxo Oncology Inc.'s highly selective RET inhibitor LOXO-292 stood out at the American Society of Clinical Oncology annual meeting as one example of where cancer drug development is going – toward cancer treatment based on the molecular underpinnings of disease rather than tissue of origin. But while Loxo presented encouraging data as a tissue agnostic approach for select patients, the importance of tissue of origin can't be ignored. Data presented on a different drug, Roche's PI3K inhibitor taselisib, from a basket trial funded by the National Cancer Institute, disappointed, highlighting the persistent challenges.

The drug industry is increasingly moving the precision medicine goalpost forward, from chimeric antigen receptor T-cell (CAR-T) therapy to next-generation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.